| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Forschungsinstitut für Molekulare Pharmakologie (A.O., G.L., S.V., K.H., G.K., W.R.), D-13125 Berlin, Germany; Institut für Molekulare Biotechnologie Jena (M.P., S.G., A.R.), 07745 Jena, Germany; Fachhochschule Jena (S.G.), 07745 Jena, Germany; Friedrich-Schiller-Universität (A.R.), Biologisch-Pharmazeutische Fakultät, 07743 Jena, Germany; and Institut für Pharmakologie (W.R.), Freie Universität Berlin, 14195 Berlin, Germany
Address all correspondence and requests for reprints to: Alexander Oksche, Forschungsinstitut für Molekulare Pharmakologie, Robert-Rössle-Strasse 10, D-13125 Berlin, Germany. E-mail: oksche{at}fmp-berlin.de.
Cloning and sequencing of the murine chromosomal region XB harboring the murine vasopressin V2 receptor (mV2R) gene and comparison with the orthologous human Xq28 region harboring the human vasopressin V2 receptor (hV2R) revealed conservation of the genomic organization and a high degree of sequence identity in the V2R coding regions. Despite an identity of 87% of the amino acid sequences, both receptors show marked functional differences upon stable expression in Chinese hamster ovary cells: the mV2R displayed a 5-fold higher affinity for [3H]AVP than the human ortholog; similar differences were found for the AVP-mediated activation of adenylyl cyclase. Saturation binding experiments with transiently transfected intact COS.M6 cells showed that the mV2R was 3- to 5-fold less abundantly expressed at the cell surface than the hV2R. Laser scanning microscopy of fusion proteins consisting of the V2Rs and green fluorescent protein (GFP) (mV2R/GFP, hV2R/GFP) demonstrated that the hV2R/GFP was efficiently transported to the plasma membrane, whereas the mV2R/GFP was localized mainly within the endoplasmic reticulum. Chimeric hV2Rs, in which the first and/or second extracellular loop(s) were replaced by the corresponding loop(s) of the mV2R, revealed that the second extracellular loop accounts for the differences in ligand binding, but the first extracellular loop accounts for the reduced cell surface expression. The exchange of lysine 100 by aspartate in the first extracellular loop of hV2R was sufficient to reduce cell surface expression, which was accompanied by intracellular retention as observed in laser scanning microscopy analysis. Conversely, the exchange of aspartate 100 by lysine in the mV2R increased the cell surface expression and resulted in predominant plasma membrane localization. Thus, a single amino acid difference in the first extracellular loop between mV2R and hV2R determines the efficiency of cell surface expression.
This article has been cited by other articles:
![]() |
F. Jean-Alphonse, S. Perkovska, M.-C. Frantz, T. Durroux, C. Mejean, D. Morin, S. Loison, D. Bonnet, M. Hibert, B. Mouillac, et al. Biased Agonist Pharmacochaperones of the AVP V2 Receptor May Treat Congenital Nephrogenic Diabetes Insipidus J. Am. Soc. Nephrol., October 1, 2009; 20(10): 2190 - 2203. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Stewart, R. Sellar, D. J. Wilson, R. P. Millar, and Z.-L. Lu Identification of a Novel Ligand Binding Residue Arg38(1.35) in the Human Gonadotropin-Releasing Hormone Receptor Mol. Pharmacol., January 1, 2008; 73(1): 75 - 81. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Fenton, L. Brond, S. Nielsen, and J. Praetorius Cellular and subcellular distribution of the type-2 vasopressin receptor in the kidney Am J Physiol Renal Physiol, September 1, 2007; 293(3): F748 - F760. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Macion-Dazard, N. Callahan, Z. Xu, N. Wu, M. Thibonnier, and M. Shoham Mapping the Binding Site of Six Nonpeptide Antagonists to the Human V2-Renal Vasopressin Receptor J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 564 - 571. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Bernier, J.-P. Morello, A. Zarruk, N. Debrand, A. Salahpour, M. Lonergan, M.-F. Arthus, A. Laperriere, R. Brouard, M. Bouvier, et al. Pharmacologic Chaperones as a Potential Treatment for X-Linked Nephrogenic Diabetes Insipidus J. Am. Soc. Nephrol., January 1, 2006; 17(1): 232 - 243. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Karges, G. Krause, J. Homoki, K.-M. Debatin, N. de Roux, and W. Karges TSH receptor mutation V509A causes familial hyperthyroidism by release of interhelical constraints between transmembrane helices TMH3 and TMH5 J. Endocrinol., August 1, 2005; 186(2): 377 - 385. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Wuller, B. Wiesner, A. Loffler, J. Furkert, G. Krause, R. Hermosilla, M. Schaefer, R. Schulein, W. Rosenthal, and A. Oksche Pharmacochaperones Post-translationally Enhance Cell Surface Expression by Increasing Conformational Stability of Wild-type and Mutant Vasopressin V2 Receptors J. Biol. Chem., November 5, 2004; 279(45): 47254 - 47263. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Sangkuhl, A. Schulz, H. Rompler, J. Yun, J. Wess, and T. Schoneberg Aminoglycoside-mediated rescue of a disease-causing nonsense mutation in the V2 vasopressin receptor gene in vitro and in vivo Hum. Mol. Genet., May 1, 2004; 13(9): 893 - 903. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Oshikawa, A. Tanoue, T.-a. Koshimizu, Y. Kitagawa, and G. Tsujimoto Vasopressin Stimulates Insulin Release from Islet Cells through V1b Receptors: a Combined Pharmacological/Knockout Approach Mol. Pharmacol., March 1, 2004; 65(3): 623 - 629. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Grantcharova, J. Furkert, H. P. Reusch, H.-W. Krell, G. Papsdorf, M. Beyermann, R. Schulein, W. Rosenthal, and A. Oksche The Extracellular N Terminus of the Endothelin B (ETB) Receptor Is Cleaved by a Metalloprotease in an Agonist-dependent Process J. Biol. Chem., November 8, 2002; 277(46): 43933 - 43941. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |